Search

Your search keyword '"Yonese, Junji"' showing total 845 results
Start Over Author "Yonese, Junji"
845 results on '"Yonese, Junji"'

1. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Published
2023
Full Text
View/download PDF

2. MP53-06 GUSTAVE ROUSSY IMMUNE SCORE PREDICTS SURVIVAL OUTCOME OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB: A MULTICENTER STUDY OF 321 PATIENTS (YUSHIMA STUDY)

Author

Tanabe, Kenji, primary, Kobayashi, Shuichiro, additional, Nagahama, Katsushi, additional, Yonese, Junji, additional, Otsuka, Yukihiro, additional, Okuno, Tetsuo, additional, Takazawa, Ryoji, additional, Noro, Akira, additional, Yano, Masataka, additional, Tsukamoto, Tetsuro, additional, Saito, Kazutaka, additional, Sakai, Yasuyuki, additional, Koga, Fumitaka, additional, Kageyama, Yukio, additional, Tanaka, Hajime, additional, Yoshida, Soichiro, additional, and Fujii, Yasuhisa, additional

Published
2024
Full Text
View/download PDF

3. MP53-13 REAL-WORD OUTCOMES OF MAINTENANCE CHEMOTHERAPY VERSUS AVELUMAB THERAPY AFTER FIRST-LINE INDUCTION CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA: YUSHIMA STUDY

Author

Izumi, Keita, primary, Tanaka, Hajime, additional, Yano, Masataka, additional, Takazawa, Ryoji, additional, Noro, Akira, additional, Tsukamoto, Tetsuro, additional, Yonese, Junji, additional, Okuno, Tetsuo, additional, Sakai, Yasuyuki, additional, Koga, Fumitaka, additional, Kageyama, Yukio, additional, Saito, Kazutaka, additional, and Fujii, Yasuhisa, additional

Published
2024
Full Text
View/download PDF

4. Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

5. Data from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

6. Supplementary Legends from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

9. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy.

Author

Fujiwara, Ryo, Yamamoto, Shinya, Takemura, Kosuke, Yuasa, Takeshi, Numao, Noboru, Oguchi, Tomohiko, Yasuda, Yosuke, Yoneoka, Yusuke, and Yonese, Junji

Subjects
CASTRATION-resistant prostate cancer, ABIRATERONE acetate, PROSTATE-specific antigen, HUMAN beings, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, KAPLAN-Meier estimator, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, ANDROGEN receptors, PROPORTIONAL hazards models
Abstract

Simple Summary: We retrospectively evaluated the clinical outcomes and prognostic factors of 127 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with first-line androgen receptor signaling inhibitors (ARSI) in real-world clinical practice. Overall survival (OS), metastatic-free survival (MFS), and prostate-specific antigen–progression-free survival (PSA–PFS) from the initiation of ARSI were assessed. The median OS and MFS for all patients were 79.0 and 42.0 months, respectively. Median PSA–PFS varied among patients treated with enzalutamide, abiraterone acetate, apalutamide, and darolutamide (27.0, 20.0, 10.0, and 14.0 months, respectively; p = 0.33). Multivariate analysis indicated that a baseline PSA level of ≥3.67 ng/mL (p = 0.002) was significantly associated with poorer OS prognosis. ARSI demonstrated favorable efficacy in nmCRPC patients, with no significant differences in clinical outcomes among different types of ARSI. High baseline PSA of ARSI was found to have a significantly poor prognosis associated with OS. We conducted a retrospective evaluation of the clinical outcomes and prognostic factors in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with first-line androgen receptor signaling inhibitors (ARSI) in real-world clinical practice in Japan. Between 2012 and 2023, a total of 127 consecutive patients with nmCRPC received ARSI treatment. Overall survival (OS), metastatic-free survival (MFS), and prostate-specific antigen–progression-free survival (PSA–PFS) from ARSI initiation were assessed using the Kaplan–Meier methodology. Clinical factors associated with OS in nmCRPC were analyzed using the Cox proportional hazards model. Among the patients, 72, 26, 12, and 17 received enzalutamide (ENZ), abiraterone (ABI), apalutamide (APA), and darolutamide (DARO) as first-line therapy. The median OS and MFS for all patients were 79.0 and 42.0 months, respectively. Median PSA–PFS was 27.0, 20.0, 10.0, and 14.0 months for patients treated with ENZ, ABI, APA, and DARO, respectively (p = 0.33). Multivariate analysis revealed that a baseline PSA level ≥ 3.67 ng/mL at ARSI initiation was significantly associated with poorer OS (p = 0.002). ARSI demonstrated favorable efficacy in nmCRPC patients. There were no significant differences in clinical outcomes among different types of ARSI therapy for nmCRP. Elevated baseline PSA at ARSI initiation was significantly associated with poorer OS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Surgical outcomes and predictive value for major complications of robot‐assisted radical cystectomy of real‐world data in a single institution in Japan.

Author

Yasuda, Yosuke, Numao, Noboru, Fujiwara, Ryo, Takemura, Kosuke, Yoneoka, Yusuke, Oguchi, Tomohiko, Yamamoto, Shinya, and Yonese, Junji

Subjects
URINARY diversion, ILEAL conduit surgery, BLOOD loss estimation, SURGICAL robots, CYSTECTOMY, SURGICAL complications, PROGNOSIS
Abstract

Objective: The objective of the study was to describe the surgical outcome of robot‐assisted radical cystectomy and predictive factors for major complications in real‐world clinical practice at a single institution in Japan. Methods: We retrospectively analyzed 208 consecutive patients undergoing robot‐assisted radical cystectomy at our institution between 2019 and 2023. Patient and disease characteristics, intraoperative details, and perioperative outcomes were reviewed. Postoperative complications were defined as minor complications (Clavien–Dindo grades 1–2) or major complications (grades 3–5). Predictors of complications were examined using multivariable logistic analysis. Results: Overall, 147 men and 61 women, median age 70 years (interquartile range, 62–77), were included in this study. Median operative time and estimated blood loss were 8.4 h and 185 mL, respectively; 11 patients (5%) received intraoperative blood transfusions. For urinary diversions, ileal conduit, neobladder, and cutaneous ureterostomy were performed in 153 (74%), 49 (24%), and 6 (3%) patients, respectively. Urinary diversions were primarily performed with extracorporeal urinary diversion. In total, 140 complications occurred in 111 patients (53%) within 30 days. Of these patients, 31 major complications occurred in 28 patients, and one perioperative death (0.5%) with a postoperative cardiovascular event. Multivariable analysis showed only prolonged operative time (odds ratio: 4.34, 95% confidence interval: 1.82–10.35, p < 0.01) was the independent risk factor for major complications. Conclusions: This study reports surgical outcomes at our single institution. Prolonged operative time was a significant prognostic factor for major complications. As far as we know, this study reports the largest number of robot‐assisted radical cystectomy cases at a single center in Japan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review

Author

Kijima, Toshiki, Fukushima, Hiroshi, Kusuhara, Shota, Tanaka, Hajime, Yoshida, Soichiro, Yokoyama, Minato, Ishioka, Junichiro, Matsuoka, Yoh, Numao, Noboru, Sakai, Yasuyuki, Saito, Kazutaka, Matsubara, Nobuaki, Yuasa, Takeshi, Masuda, Hitoshi, Yonese, Junji, Kageyama, Yukio, and Fujii, Yasuhisa

Published
2021
Full Text
View/download PDF

18. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

20. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

22. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, additional, Kawahara, Takashi, additional, Matsumoto, Ryuji, additional, Miyake, Hideaki, additional, Matsubara, Nobuaki, additional, Uemura, Hiroji, additional, Eto, Masatoshi, additional, Azuma, Haruhito, additional, Obara, Wataru, additional, Terai, Akito, additional, Fukasawa, Satoshi, additional, and Suekane, Shigetaka, additional

Published
2023
Full Text
View/download PDF

25. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data

Author

Hinata, Nobuyuki, Yonese, Junji, Masui, Satoru, Nakai, Yasutomo, Shirotake, Suguru, Tatsugami, Katsunori, Inamoto, Teruo, Nozawa, Masahiro, Ueda, Kosuke, Etsunaga, Toru, Osawa, Takahiro, Uemura, Motohide, Kimura, Go, Numakura, Kazuyuki, Yamana, Kazutoshi, Miyake, Hideaki, Fukasawa, Satoshi, Ochi, Kenya, Kaneko, Hirokazu, and Uemura, Hirotsugu

Published
2020
Full Text
View/download PDF

31. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

Author

Uemura, Hirotsugu, Uemura, Hiroji, Nagamori, Satsohi, Wakumoto, Yoshiaki, Kimura, Go, Kikukawa, Hiroaki, Yokomizo, Akira, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Akagawa, Takashi, and Matsubara, Nobuaki

Published
2019
Full Text
View/download PDF

33. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

34. Real‐world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST‐NIVO study): 36‐month follow‐up results of a clinical chart review

Author

Yonese, Junji, primary, Hinata, Nobuyuki, additional, Masui, Satoru, additional, Nakai, Yasutomo, additional, Shirotake, Suguru, additional, Takeuchi, Ario, additional, Inamoto, Teruo, additional, Nozawa, Masahiro, additional, Ueda, Kosuke, additional, Etsunaga, Toru, additional, Osawa, Takahiro, additional, Uemura, Motohide, additional, Kimura, Go, additional, Numakura, Kazuyuki, additional, Yamana, Kazutoshi, additional, Miyake, Hideaki, additional, Fukasawa, Satoshi, additional, Morishima, Naoto, additional, Ito, Hiroaki, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

35. Prognostic Significance of Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated With Immune-checkpoint-inhibitors

Author

YASUDA, YOSUKE, primary, FUJIWARA, RYO, additional, OGUCHI, TOMOHIKO, additional, KOMAI, YOSHINOBU, additional, NUMAO, NOBORU, additional, YAMAMOTO, SHINYA, additional, OKI, RYOSUKE, additional, URASAKI, TETSUYA, additional, TAKAHASHI, SHUNJI, additional, YONESE, JUNJI, additional, and YUASA, TAKESHI, additional

Published
2023
Full Text
View/download PDF

37. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Author

Matsubara, Nobuaki, Nagamori, Satsohi, Wakumoto, Yoshiaki, Uemura, Hirotsugu, Kimura, Go, Yokomizo, Akira, Kikukawa, Hiroaki, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Tsutsui, Hirokazu, and Uemura, Hiroji

Published
2018
Full Text
View/download PDF

40. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?

Author

Soyano, Takashi, primary, Kozuka, Takuyo, additional, Kashihara, Kenichi, additional, Murakami, Yu, additional, Yonese, Junji, additional, Sasamura, Kazuma, additional, Shimoyachi, Nana, additional, Kashihara, Tairo, additional, Yoshioka, Yasuo, additional, and Oguchi, Masahiko, additional

Published
2023
Full Text
View/download PDF

43. Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study

Author

Waseda, Yuma, Saito, Kazutaka, Ishioka, Junichiro, Matsuoka, Yoh, Numao, Noboru, Fujii, Yasuhisa, Sakai, Yasuyuki, Koga, Fumitaka, Okuno, Tetsuo, Arisawa, Chizuru, Kamata, Shigeyoshi, Nagahama, Katsuji, Masuda, Hitoshi, Yonese, Junji, Kageyama, Yukio, Noro, Akira, Tsujii, Toshihiko, Morimoto, Shinji, Gotoh, Shuichi, and Kihara, Kazunori

Published
2016
Full Text
View/download PDF

44. Additional file 3 of A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Abstract

Additional file 3: The consent form given to participants.

Published
2023
Full Text
View/download PDF

45. Additional file 2 of A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Abstract

Additional file 2: The explanatory document translated to English (the original document is written in Japanese).

Published
2023
Full Text
View/download PDF

46. Additional file 1 of A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Abstract

Additional file 1: SPIRIT 2013 Checklist for the MEDAL trial.

Published
2023
Full Text
View/download PDF

47. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study

Author

Fujiwara, Motohiro, primary, Yokoyama, Minato, additional, Toide, Masahiro, additional, Fujiwara, Ryo, additional, Tanaka, Hajime, additional, Oguchi, Tomohiko, additional, Komai, Yoshinobu, additional, Yoshida, Soichiro, additional, Matsuoka, Yoh, additional, Numao, Noboru, additional, Yamamoto, Shinya, additional, Fukui, Iwao, additional, Yonese, Junji, additional, and Fujii, Yasuhisa, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results